"Location, location, location" is a real estate adage, but it could also be the buzzwords of nascent biological reagent provider Intrexon, which this week said it closed a $1 million round of private equity financing to help develop and market its line of location-dependent sub-cellular genetic tools.

Intrexon's technology is based on the theory that knowing the location of sub-cellular events may determine a distinct phenotype, a notion that the company believes is growing among researchers. As the company's CEO puts it, "location matters."